Kenny Green
Investor Relations at Edison Group
Replay available
Evogene (NASDAQ:EVGN) Q3 2020 earnings call, held 2020-11-18. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/evogene-ltd-evgn-q3-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, thank you for standing by. Welcome to Evogen's third quarter 2020 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. As a reminder, this conference is being recorded November 18, 2020. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogen's and Evagen Subsidiaries Management will constitute forward-looking statements that relate to future events, risks and uncertainties regarding business strategy, operations and future performance and results of Evagen. These statements may be identified by words such as may, could, expects, intends, anticipates, plans, believes, scheduled, estimates or words of similar meaning.
0:51 For example, Evagen is using forward-looking statements in this earnings conference call When it discusses its and its subsidiaries' targets, objectives, pipeline, and goals, and the expected timing thereof, its support of its subsidiaries, the sufficiency of its funding to achieve key objectives, and to continue to enhance and expand its computational predictive biology platform, its estimated cash usage for 2020, capturing the value of its technologies and subsidiaries, entering into collaboration agreements, It's Upcoming Milestones and Potential Alternatives to Capitalize on the Company's Subsidiary's Achievements. I encourage you to review Evagen's filings with the U.S. Securities and Exchange Commission and read the note regarding forward-looking statements in their earnings releases, which states that statements made in those earnings releases and in a similar way on this earnings conference call that are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
1:50 All forward-looking statements made herein speak only as of the date of the announcement of results. Therefore, actual future results, performance or achievements of Evagen and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evagen and its subsidiaries, including, without limitation, the global spread of COVID-19 or the coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evagen's reports filed with the applicable securities authorities. In addition, Evagen and its subsidiaries rely and expect to rely on third parties to conduct certain activities, such as their field trials and preclinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, including as a result of the effect of the coronavirus, Evagen and its subsidiaries may experience significant delays in the conduct of their activities. Evagen and its subsidiaries are under no obligation to update publicly or alter our forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.
3:06 Evagen and its subsidiaries expressly disclaim any obligation to do so. More detailed information about the risk factors potentially adversely impacting our performance can be found in our reports filed with the U.S. Securities and Exchange Commission. That said, I would now like to turn over the call to Ofer Haviv, Avigin's CEO. Ofer, please go ahead.
3:28 Thank you and good day, everyone. We appreciate you joining us today to our third quarter 2020 conference call. Joining me today is Ms. Dorit Kreiner, our CFO, and Dr. Eran Hever, CEO of our subsidiary, Biomica. I will begin my comments today by providing an overview of the company's various activities, some context to our recent fundraising, and discussing our plans to unlock the value of our subsidiaries. I will then hand the call over to Elran to discuss Biomica's activity in more detail, focusing specifically on its Immune Oncology program and the recent progress. Following Elran's comments, The week will summarize Evogen's financial results for the third quarter of 2020. We will then open the call for your questions.
4:21 Before I begin my comments, I would like to address the impact of the COVID-19 pandemic on Evogen's operations. I am pleased to say that to date, the impact has been minimal. As of today, the company has resumed full activity. While we are fully operational, I want to ensure our shareholders that the company and its employees are working in compliance with the restrictions and guidelines provided by the Israeli health authorities and other applicable governmental authorities and will continue to do so. So let's start. I would like to begin by taking this opportunity to thank our shareholders, new and old, for the continuous support of the company.
5:08 As the company enters a new era, Advancing its technological platform through three product solutions, MicroBoost AI, Campus AI, and Generator AI, and with its subsidiaries progressing towards the development of valuable assets and commercialization, we hope to continue to earn your confidence. For our new investors, I would like to give a brief overview of our company's activities. As you know, Avogen's vision is to revolutionize life science product development by utilizing computational biology technologies. With so many complex challenges associated with the development of biological-based products, including high development cost, low development time, and most importantly, low probability of success, we believe that now is the right time to leverage the revolution in the computational world to biology.
6:05 Over the last decades, At an investment of tens of millions of dollars, incorporating deep scientific understandings together with big data and artificial intelligence, Avogen has developed a unique computational predictive biology platform. This proprietary technology is called the CPB platform. Today, building on this technology, Avogen has three product solutions that we believe will help to accelerate and direct life science product development based on the following core components, microbes, small molecules, and genetic elements called MicroBoost AI, Campus AI, and Generator AI, respectively.
6:51 We aim to capture the value of these three solutions through two avenues, product development through partnerships at the parent company level, and product development through our subsidiaries. Throughout Evogen's early years, We focused largely on the first avenue, partnered with leading companies for defined products using Avogen technology, while later stage development and commercialization of the product was typically undertaken by the partners. This avenue was our main business model until about 2014. During those years, Avogen was engaged with leading ag companies including Bayer, DuPont, Monsanto and Syngenta, mainly for the development of new GMO seed traits. Looking forward, we aim to engage in partnerships along this business model in additional market segments.
7:51 The second avenue for capturing the value of Evogen's technology is product development through its subsidiaries. Evogen established subsidiaries to focus on the defined commercial field with an exclusive license to use the CPB platform in their respective field of activity. I would like to emphasize that these subsidiaries may commercialize their future products either independently or with partners according to the product type and end market. Some of the strategic partnerships Evogen subsidiaries currently have are with world-leading companies such as BASF and Corteva. Today, Abogen has several main subsidiaries under this business model as follows.
8:39 In the area of human health, we have Biomica, which aims to provide therapeutics based on microbes that exist in the human gut. Currently, Biomica has three main product programs based on microbes. The first to improve the efficacy of immune therapy, the second to provide therapeutics for IBD and the third to provide therapeutics for IBS. The latter two of which are GI-related disorder. Avogen holds approximately 90% of Biomica. During the quarter, Biomica announced positive preclinical results in its immune oncology program. These results showed that Biomica live biotherapeutic drug candidate BMC-128 given prior to and in combination with immune checkpoint inhibitor significantly improved anti-tumor activity.
9:42 This program was further strengthened by the initiation of scale-up and GMP batch production of BMC-128, which we also announced during the quarter, in order to support Biomica's anticipated first-in-men proof-of-concept and clinical trial to be initiated next year. Elran, who will be speaking in few moments, will give more information on this program and other programs Biomica is advancing. The second company in the area of human health is Canonic, active in the area of medical cannabis. Canonic aims to develop two types of product. The first is meta-yield, cannabis varieties with overall increased yield and the second is precise.
10:33 Increased yield of specific compounds in the plant to address medical indications such as inflammation and pain. Avogen holds 100% of Canonic. Canonic recently announced that it has received approval from the Israeli Medical Cannabis Agency for the propagation of medical cannabis seedlings This will allow Canonic to proceed with the execution of its commercialization plan. As you might recall, Canonic aims to release its first product in Israel in 2022. Moving on to agriculture, the first company in this area is Agplanus, which is active in the development of other chemicals.
11:22 Agplanus is focused on the development of two main types of crop protection products. Novel mode of action herbicide and new type of action insecticide. Avogel holds approximately 98% of Agplanus. I would like to take this opportunity to congratulate Doug Eisner for joining Agplanus in September as its new CEO. Doug brings over 20 years of versatile business and legal experience, previously holding various senior leadership roles, and leading successful fundraising grants and accompanying acquisitions. I have no doubt that DAG will have an important contribution to the success of this company and achieving its targets in the next few years, focusing on advancing our strategic relationship with Corteva and BSS and advancing our internal novel herbicide pipeline.
12:19 The second company in agriculture is LaviBio, focused on agri-biologicals. Within this field, the company is focused on two main types of live microbial products. The first is biosimulants, which when applied to the plant, improve its performance. The second is biopesticides, which when applied to the plant, protect it from pests such as fungi and insects. Avogen holds approximately 72% in NaviBio, with Coteva, a world-leading ag company, holding the remaining 28% following its investment in the company in 2019. La Vie Bio recently announced positive results in its bio-fungicide program for Lab 311 and Lab 312. These positive results were achieved in a series of vineyard trials for Banshrath disease conducted in Europe and the United States and show that Winiard treated with each of Lab 311 and Lab 312 demonstrated 60-70% reduction in crop damage in comparison to the control.
13:38 I would like to note that this was only a short overview of the company and its subsidiaries. We have prepared some great informational materials on each of these subsidiaries. and I urge you to view the presentation section on our website to view these materials. Moving on, I would like to provide some more information on Evogen's recent fundraising activity. I would like to start by emphasizing that over the years, Evogen has taken a very disciplined approach to its capital allocation and the company has made significant developmental progress over the years with the resources it had. During the past year, the subsidiary's advancement was very rapid and in certain areas even exceeded plans.
14:32 Therefore, we decided to raise additional funds in order to support their ambitious business targets. I'm pleased to say that Avogen recently completed two rounds of fundraising totaling $22 million. I'm also pleased to say that the investors that took part in those fundraisings are top-tier institutional investors, including ARK Invest. I would like to note, for those of you who are not familiar, that ARK is one of the world's leading innovation funds investing in the technologies of tomorrow, and we are honored to be part of their distinguished portfolio.
15:17 As published, Evergen Intend to use the net proceeds from the fundraising to further develop its subsidiaries' product pipeline, to enhance and expand its computational predictive biology platform, and for working capital and general corporate purposes. Looking forward as a whole, we intend to continue to be capital efficient while working toward our business targets, which include the following. In Biomica, We intend to support preclinical and clinical trials. In canonics, we intend to support development of unique varieties as well as cultivation and commercialization of its medical cannabis products.
16:06 In ag planus, we intend to support herbicide development towards the stage of optimized lead as well as expand the insecticide program. In LaviBio, we intend to support the route to commercialization of wheat biostimulants, as well as support the product development in its biopesticide programs. Evogen also intends to enhance and expand its product solutions, microboost AI, campus AI, generator AI, in order to maintain its technological and computational competitive advantage. Evogen expects to extend its efforts in genome editing and to capitalize on its legacy seed trade activities.
16:55 With both these rounds of fundraising, we believe that Evogen and its subsidiaries have the funds to support their near-term business objectives, including reaching important milestones, such as initial sales in Labibio and Canonic, and valuable assets in Atlantis and Biomica's product pipelines. I also would like to mention that these capital raises bring us closer to the opportunity to unlock the value of our subsidiaries. Reaching the important development milestone we outlined in our company presentation could put our subsidiaries in an attractive situation on capitalized owner achievements, such as in the form of investment of a strategic or financial partner, M&A, or even an IPO.
17:46 To summarize, it has been a very productive quarter for Evogen and we are pleased with the advancements made in our subsidiaries despite the objective difficulties COVID-19 has presented. I would like to once more thank our investor community for their support in the company. I will now turn the call over to Dr. Elran Hever, CEO of Biomica. Elran?
18:16 Thank you, Ofer. I'm happy to be on the call today. Let's start with a short introduction on Biomica. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated and infectious disease. Biomica's underlying premise is that our gut microbiome, or basically the microbes that live in our gut, has an impact on our health and play a significant role in a wide area of illnesses. This has been well documented in scientific literature and is supported by an increasing body of clinical evidence. The main question that most of the microbiome companies are now facing is to know how to identify the microbes that provide the desired effect.
19:04 Biomeca aims to answer this question through the use of computational biology. At Biomica, we aim to discover and develop novel therapies for microbiome-related human disorders using a rationally-based design approach enabled by computational predictive biology. In this regard, Biomica has exclusive access to Evagen's proprietary technology, the CPB platform, which was developed over the past decade into an investment of tens of millions of dollars. The potential of the microbiome is clear to the big pharma. and virtually every company now is taking stake in this space. Since 2014, more than $4 billion has been invested in microbiome companies. Rapidly growing with a projected 70% of compound annual growth rate, according to recent market reports, the microbiome market space provides a multi-billion dollar market opportunity. Biomeca is focused on the unmet high-value clinical programs, including three domains.
20:04 The first is immunooncology, immunotherapy. The second are GI-related disorders, gastrointestinal-related disorders. And the third are antimicrobial resistance. In our call today, I would like to focus mainly on our immunooncology program. It has been shown in various studies published in the scientific literature that one of the key reasons that some patients may not respond to immunotherapies is due to the differences in their patients' microbiome. One example of this, which you might have heard of, is the use of FMT. FMT stands for fecal microbiota transplantation, in which out of two groups described, some patients who initially did not respond to immunotherapy drugs show positive response after receiving a stool donation from patients for whom drugs worked.
20:58 The main unresolved question is exactly which microbes help to obtain the desired immune activity. Our program's initial target is to identify the microbes which can improve the efficacy of immune checkpoint inhibitors, or ICI shortly, that are the leading therapy today for cancer patients. Using Biomedica's computational biology platform, PRISM, that is powered by Evagen's MicroBoost AI, we were able to rationally design two live bacterial products each comprised of four unique bacterial strains which are naturally inhibitors of the human intestinal tract. These strains harbor specific functional capabilities which have the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.
21:53 Rational Design's bacterial consortia are multi-strained products designed to restore diversity and specific functionality to the host microbial community. These drug candidates were tested together with immune checkpoint inhibitors in a preliminary preclinical trial in 2019 and presented positive results with improved anti-tumor activity in mice. After careful analysis of these results, we decided to focus on four strains right from our initial two drug candidates with the highest functionality. This led to the design of our leading drug candidate, BMC128. In 2020, we continued with a broader preclinical trial, testing our drug candidate in various dosing protocol Not only in addition to immunotherapy, but also as a pre-treatment or prior to the immune checkpoint inhibitor therapy.
22:52 In this trial, the animals were divided into various treatment groups and BMC-128 was administered to mice bearing cancer tumors prior and during ICI therapy. In September of this year, we announced the positive results of these trials demonstrating that the treatment with BMC-128 prior and in combination with administration of immune checkpoint inhibitors significantly reduced the tumor volume and increased animal survivor compared to immune checkpoint therapy alone. It seems that Biomica's bacterial consortia administered prior to immune checkpoint inhibitor therapy primed the immune system for an efficient and well-orchested anti-tumor response ultimately leading to the most reduced tumor volume and the best survival rate out of all groups. The response to the combination treatment was 50% higher in comparison to the group that received only immune checkpoint inhibitors therapy.
23:59 Looking forward in 2021, the company aims to enter proof of concept clinical trials in Israel. For this purpose, Biomica contracted the services of BIOS industry, a leading France CDMO, for a scale-up production of our microbes according to GMP standards. The large-scale production of our leading drug candidate, BMC128, has been initiated following the successful completion of the initial R&D stage of the drug product development and manufacturing. Now, I would like to update you that we are currently in discussions with a number of leading medical centers in Israel regarding conducting this proof of concept study, pilot study, in 2021.
24:47 In regards to our other programs, just a quick note. We are currently advancing our IBD program in the preclinical phase, having initiated new preclinical studies at the University of North Carolina at Chapel Hill. at the lab of Professor Balfour Sartor, who is a Biomedical Scientific Advisory Board member and is one of the leading researchers and thought leaders in IBD in the US. In regards to our IBS program, this is progressing according to the plans and we are currently concluding the discovery phase with the computational identification of microbes with the desired functionality to address this disorder. I would like to end by mentioning that we have recently been seeing an announcement of companies in the microbiome space regarding positive phase 3 clinical data.
25:38 These announcements provide strong validation for the utilization of microbiome therapeutics and help to validate biomical science and clinical approach and demonstrate the potential value proposition of biomica. With that, I would like to turn over the call to Dorit.
25:59 Thank you Elran. I will begin by reviewing our cash balance, which includes approximately $43.5 million in consolidated cash, cash-related accounts and bank deposits as of September 13, 2020. This amount includes a $10 million investment received by the company during September. I would like to add that approximately $13.6 million of Evergen's consolidated cash is appropriate to its subsidiary, La Vie Bio. The September 30 cash balance does not include an additional investment of $12 million received after the date of the financial report. During the first nine months of 2020, the consolidated net cash usage was approximately $13.4 million, or $9.3 million if excluding LaviBio.
26:56 During the third quarter, the consolidated net cash usage was approximately $4.6 million or $3 million if excluding LaviBio. For the full year of 2020, we continue to estimate that our net cash usage excluding cash usage of our subsidiary LaviBio will be within the range of $13 to $15 million. The company does not have bank debts. Let's now turn to the statement of operations. R&D expenses for the third quarter of 2020 were approximately $4 million in comparison to $3.6 million in the third quarter of 2019. R&D expenses were mainly attributed to preclinical trials in Biomeca Phil Trice for Laveed Bio, and Svetanin Evogen Technology with new capabilities.
27:51 General and administrative expenses for the third quarter of 2020 were $1.2 million in comparison to $0.9 million in the third quarter of 2019. This increase is mostly attributed to an increase in the cost of companies' D&O insurance. Operating loss for the third quarter of 2020 The increase in loss is attributed to the increase in operating expenses and a decrease in net financing income. With that said, we would like now to open up the call for any questions you may have.
28:50 Operator? Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you have a question, please press star 1. If you wish to cancel your request, please press star 2. If you are using speaker equipment, kindly lift the handset before pressing the numbers. Your questions will be polled in the order they are received. Please stand by while we poll for your questions. The first question is from Kristin Kluska of Cantor Fitzgerald. Please go ahead.
29:23 Hi, good afternoon everyone. Hope you're all doing healthy and well at this time. So I had a few questions related to Biomica. So the first is, Regarding this BMC-128 data, could you please discuss what some of the remaining preclinical work that you're hoping to conduct is? And then how are you starting to think about some of the early thoughts related to the proof of concept study next year? So for example, how long do you think it takes for BMC-128 to condition the immune system? And then given the unique nature of microbiome-based medicines, how do you think about testing different dose levels and disease states of these patients, considering that's a limitation for a lot of other therapies in development right now.
30:14 Sure. Thank you, Christine. So as for BMC-128, we have conducted a number of practical studies so far, and we are aiming now mainly to optimize the dosing regimen for BMC-128 and to evaluate the effectiveness of this drug candidate in additional tumor types. So this is in part what we are doing in means of preclinical trials. As for our incident proof of concept in humans, this is something that we announced is aimed to be in 2021, the second half of 2021, in which we are currently scaling the production and preparing the clinical batch for its proof of concept study.
31:01 I would say that in means of how we are addressing the dosage, I think one of the things is related to our unique approach in which we are trying to minimize the number of strains that we are providing the patient in order to obtain the desired therapeutic effect. So we are basically trying to maintain the standards of dosing in means of microbes, but since we are using less numbers of strains, eventually the drug product would be something that could be more easily administered to patients. So I think this is in part. We are evaluating a number of different dosing as well in preclinical models, so this is some insights that we will have more in the near future.
31:57 Thank you. And then on your comment related to, you know, looking at different tumor types here, I was wondering if we could take a step back and I know, you know, initial focus might include NSCLC, but, you know, broadly speaking, how do you look at the landscape? So, for example, which cancer types would you view as having the greatest unmet need based off of the low response rates that are observed for immune checkpoint inhibitors alone?
32:24 So obviously non-small cell lung cancer is one of the tumor, the unmet medical needs that obviously need to be addressed since the response rate in this type of cancer is very low. But we are also aiming for other types of solid tumors. So one of the things that we are evaluating now is the effectiveness in RTC. We know based on the data that we walked from the clinical data source that we analyzed that RTC and non-small cell lung cancer basically obtained the same results for us, so we are pretty certain that it could be an additional indication that we could pursue. Also, I think that other types of solid tumors, as melanoma, could be relevant, so we are not necessarily limited to non-small cell cancer, and potentially the proof of concept that we'll conduct could include patients from various types of solid tumors.
33:21 Okay, great. Thanks so much for taking the question.
33:24 Sure. The next question is from Steven Goldman. Please go ahead.
33:33 Oh, yes. Hello, and congratulations on the progress you've made over the last number of months. It's been quite impressive. I have a few questions regarding Biomica, Ag Planetis, and Labibio. And with respect to Biomica, When are you planning to provide more detailed data from your preclinical trials that you've conducted?
34:01 Hi, Steven. Thank you for the question. So we've shared some additional data in the recent presentation that was shared by Evagene. And I think one of the new updates was also in the call today, so we've announced that received 50% additional response in comparison to the immune checkpoint inhibitor therapy. But we are planning to present the entire set of results in one of the most, I would say, important conferences in the microbiome space. It will be the largest European microbiome conference. It will be in January. And we will present the entire results in this conference.
34:46 Okay, thank you. I look forward to hearing that data. Can you provide just a little explanation of sort of the process in Israel? You refer to it as the proof of concept pilot study. I take it that's similar to a phase one study that you would see in the U.S.?
35:11 Not identical, but it's similar to Phase 1, Phase 2A kind of study. Basically, we'll have a small group of patients. It will be those, so it will be patients, cancer patients, not health individuals. The numbers will be approximately between 10 to 15 patients. All of them failed prior immunotherapy, and we will treat them with a combo treatment of our micro BMC-128 and immunotherapy. It will take place in one of the leading medical centers in Israel, at least one of them. We are now evaluating maybe to expand to additional sites in Israel, but this is something that currently is under discussion. Let me know if you have additional questions regarding this.
35:59 No, that's fine. I guess we'll learn more about the process as time goes on. What plans do you have to take this to the U.S.? Are you going to use the data from your initial Israeli study to get an IND in the U.S.?
36:17 Absolutely, yes. I think one of our objectives in this Israeli study is not only just to evaluate the safety, to some extent the efficacy, but it will be also to collect data that we could use in our IMB discussions with the FDA and to initiate our studies in the US, I believe in 2022. So that's the main idea. I think one of the advantages working in Israel, it will allow us to get quicker to first-in-man studies. and to be able to use the data that will be collected from the study in our discussions with the US FDA.
36:58 Okay, thank you. And finally, my last question for you, Alron, is do you have any comments or observations you can make as to why you think Biomica's approach with its, I guess its four-strand microbiome therapeutic candidate would do better than, for example, one of your competitors is using a single-strand microbiome candidate also for immunotherapy.
37:29 Definitely, yeah. So I think one of the advantages working with a rationally designed live biotherapeutic product in comparison to a single-strand method is the ability to provide a patient with targeted immunotherapy We are aiming to affect the disease by a number of modes of actions and a single strain is limited by the number of modes of action that it could affect. By combining and providing more strains but with a certain amount, not providing thousands because it could actually provide us with a higher risk potential, you are basically enhancing the potency, the effectiveness of this drug product in comparison to a single strain method in which you are basically limited by the number of modes of actions that this single microbe could affect.
38:29 I see. Well, we look forward to seeing your data as it comes out. Thank you, Alron. I have a couple of questions regarding ag planus. Does this go back to Ofer? In your press release, in discussing the use of the $22 million of funds recently raised, you discussed that some of the funds will be used for Agplenis' development of its herbicide. I assume that's HERB32 from a lead to an optimized lead. But I have not seen, and perhaps I missed this, Is CERT32 now officially a lead?
39:14 So the answer is no. We didn't officially announce our candidate as a lead. We are now collecting the data from the field experiment conducted by a third party in USA. and we are expecting to finalize this process including the statistics hopefully in the next two weeks and I hope that then based on these results we can announce hopefully achieving the lead phase. So when we mention and yes this is what we include that we are planning to use parts from the money we raise to support This candidate moved from the lead to optimized lead stage.
40:07 It was based on the assumption, hopefully, that we will get a positive result. We are all expecting to see what is the result with a lot of enthusiasm and a lot of excitement because it's going to be quite an important step for Act Planus. Still, I would like to mention that there is a gap between lead and optimized lead. which this is the next step that I was mentioned that we are going to support financially during next year. The Tevogen is planning to support expanders in achieving this target because based on the market analysis we did, the value of optimized lead in the eyes of the big guys is quite significant compared to lead because you have more safety data, more efficacy data, more field trial data, and this is all type of things that we can do, we can achieve them, assuming that we will achieve the LEED phase and especially I'm feeling comfortable because I'm relying on the Evogen technology to optimize, if needed, our LEED components.
41:18 So to summarize, yes, we are going to support ag planus activity, moving from LEED to optimized LEED. We didn't announce yet that we reached the lead phase. It's something that we are planning to hopefully to be able to achieve till the end of this year and are really looking forward, assuming we achieve this target, that it reach also to the optimized lead phase because this is where the big, big money is. Yes, that's my understanding.
41:49 And your advanced candidate, HER32, is that how you describe it? I take it that's a that would be a potential replacement for like Monsanto's or Bayer's Roundup. Is that right Mike? Is that my understanding correct?
42:07 Yes, you know this type of a product again we need one of the things that we now also validate is what is the type of weed that it's really effective against. What is really nice and I really hope that we also will be able based on the results of course to disclose The ability of our small molecules to address the resistance issue that was developed in different type of a weed which you know if you have not just an effective but also with a new mode of action herbicide this is have a lot of value. Still there is the question you know you need to validate in what geography it work and What is the level of efficacy on the different weeds? But we are now feeling quite positive about the early results we received, and we are looking forward to see the additional results that should come from our trial this year and next year.
43:06 Okay.
43:07 Well, I look forward to the news when it gets released. And finally, just a couple of questions regarding Labibio. Your most advanced product is your Lab 211, which is a biostimulant. And if I recall, when I last was looking at this, you had hoped that you would be in commercial sales by early 2022. But what are your plans now in 2021 for next year? for Lab 211.
43:47 So first, we are now collecting the results from two areas where we conduct field trials for Lab 211. First one is in North Dakota. The second one is in Montana. And I believe that, again, until the end of this year, we will give a short update on our BIT program. Spring Wheat Program and also some other programs that we are now gathering the results and the statistics. So this is one thing that we are planning to do still this year. And next year, the idea is that we are going to validate our Lab 211 in a commercial level, meaning that we are going to distribute Lab 211 to big regular farmers. It's going to be a part from their ongoing activity.
44:40 and hopefully to see the results. And this will be probably the last phase before we can start to initial the commercial activity for this product, which is expected, as you mentioned, to take place in 2022. So summarized, next year, commercial field trials, big farmers are going to use this candidate.
45:09 Okay. And are you able to provide any feedback? So that's the spring wheat market that you're initially going after. And are you able to provide any feedback on that size of that market and your marketing strategy?
45:26 So for people that may be less aware, there are two types of wheat, spring wheat and winter wheat. We are focusing on the spring wheat. It's a smaller market compared to the winter wheat, but still it's quite significant. We didn't disclose number, but there is two options how you can reach through the market with this product. We can use local distributors or we can work with one of the big companies. We are now evaluating these two channels. There is an interest in both directions from the other side, from big companies or from the local distributors, so we are in good shape in validating these two opportunities.
46:15 When we get more close to the launch, the commercial launch, I believe we can disclose more detailed information and what is our final decision.
46:28 Okay, that's great. And finally, I guess some weeks ago, Labibio announced the positive trial results from Lab 311 and Lab 312, and those are biopesticides, I guess, for use in the grape rot, etc. So what are the next stages in development there, and what's the significance in terms of market size, etc.? ? and Timing.
47:00 Okay, so let's start with the last question. So Timing, I think in the press release you mentioned that the commercialization of this product, it will take more time than the Lab 211. Here you're talking about the fungicide, so the regulation process is a little bit longer. So we expect to reach through the market at 2024. Please remember the slab 2-1-1 is expected to reach the market in 2022. So first product 2022, second product 2024. So this is with respect to timing and next year we are expecting to conduct a broader field trials in more locations.
47:46 I can tell you that this is one of the most lucrative type of product for We are very excited about this opportunity. With respect to the results, we didn't disclose specific numbers, but what we mentioned is that the performance of our candidate was better than the competitor, meaning other ag biological products that are trying to address the same fungi. But we also mentioned, and this is for me very important, that it's showing a nice result even compared to the chemical product. And this is a very strong statement because usually if there is a disadvantage to ag biologically, it's usually their performance are not close to a synthetic molecule.
48:52 and if we are claiming that we feel comfortable using our product even compared to chemistry, this is a very strong statement and also can reflect what could be the gap between our product and what is available today in the market when you're talking about biofungicides. So we are really very excited and I think that we also add a nice picture to the press release So sometimes, you know, even a picture can send a very nice message. And it was just one example from the picture that we got from this field trial. So we are very excited from this specific problem.
49:34 So how does your Lab 311,312 compare in terms of toxicity compared to what's currently being used?
49:47 You're talking about the efficacy?
49:51 No, toxicity.
49:55 So I'm not sure that I have it. Toxicity. Toxicity. So I think that I would, I think this type of question I need to ask Ido, the CEO of Biomica. Sorry, Lavi Bio. I don't have this information in front of me. So I don't want to say something that I'm not sure about.
50:22 Okay. So what is the advantage of the product compared to the competition that's out there now?
50:35 Currently what we are talking about is mainly the efficacy. And efficacy is how you reduce the damage of the fungi in the vineyard. compared to the other product in reducing the effect of the fungi that we are trying to address.
50:54 The idea of AgBiological is that they are supposed to replace or reduce
51:15 The need of a chemistry because ag biological, you know, this is a microbe that exists in nature and the whole idea of using ag biological is that they are supposed to be greener to use versus the ag chemical. So this is the main reason why there is a strong trend of using The next question is from Jeff Gilbert of Iniksjuk Investments. Please go ahead.
51:59 Good afternoon, Ofer. Congratulations on your recent momentum. I just have two questions for you. If you don't mind, if you could comment on the level of engagement from each of your large ag partners. Specifically, have there been any interruptions in regard to the pandemic? And I'm wondering if you can comment also specifically on Bayer. Are they more engaged or still on hold after the acquisition of Monsanto?
52:30 So, Monsanto has been acquired by Bayer and the agreement that we were committed to Monsanto, they were also transferred to Bayer. Last time we checked, they are still holding the shares that Monsanto holds in Evogen, so nothing changed in their holding in the company. This was one of your questions with respect to the engagement. And we have two ongoing collaborations with them. One of them is in the field of improving seed rate for Fusarium. So this is an ongoing program. Actually, the last time that I looked into the annual report of a buyer, when they described their ongoing collaboration, so they mentioned in their chart their relationship with Evogen.
53:29 The second collaboration that we were, that was transferred from Montana to and a buyer, it was the Yield and Ability Stress Collaboration Agreement, developing a GMO product. So this is also on, they are still working on some of the genes that we deliver to them. I can't disclose much because of the confidential agreement that we have with them. but this collaboration agreement was also mentioned in their annual report as part from their relationship with BASF in the field of improving yield and the drought tolerance in corn and soybean via GMO type of products. So I hope that I answered your question if I understand it correctly.
54:22 Yeah, in general it sounds like More engaged than they might have been the last few years when they were trying to digest Monsanto, is that correct?
54:33 I think that now when the buyer acquired Monsanto, I can imagine that this is the beginning. It wasn't easy to swallow such a big company, but now things are moving more smoothly and We are in contact with them on a regular basis, and we have some of the people that we know very well in Monsanto. Today they are in a major role in Bayer, so we also have a good relationship with the Bayer management team these days.
55:15 That's great to hear. I know there's a lot to cover and so I appreciate your general overview as well at the beginning of the call. Just my final question. You mentioned a couple of times the commercialization plan for Canonic. I was wondering if you could give a little bit more detail there. Is that direct to market? Are you going to produce traits and then license them and sell them? Can you give more detail?
55:40 So I think that there are certain Product family that we are targeting. The first product, and it will be based mainly on evogen phenotypic technology to identify from a very broad germplasm some very promising lines that even without improving them in a sophisticated genomic technology, They will reach to the market and show a high standard. And this will be the first product that is expected to be launched in 2022. Actually, this quarter we announced that we received the approval for fiddling greenhouses to grow cannabis filling and then we can deliver them to third parties to grow it here in Israel. and then we can produce the product that will be ready for sale.
56:47 So, through this announcement, in a way, we complete the full pathway to commercialization. The second product, the second type of product which is expecting to reach the market in 2023, it will be a unique variety that will be based on breeding using what is called genomic markers that we are now identifying using Evogen technology. And this product will show a unique criteria compared to what exists today in the market.
57:32 In the mid-term, from 2023 and on, I'm expecting to see more and more unique type of product that will be based not just on Evogen technology, but also on some medical or preclinical study that we are conducting around this product, which later on all of this information is integrated into our system in order to identify specific pathways and how to modify the genomics, not necessarily through GMO approach. It could be what is called mutagenesis or maybe even genome editing technology. So in order to improve specific manufacturing of specific cannabinoids, that again, it can address specific needs in the medical cannabis area.
58:25 So the first product reaching to the market will be mainly based on the unique technology of what is called phenotypic, meaning to identify based on the existing genomics of the crop what could fit to the market needs. Then immediately after this, there will be unique lines based on evergen technology using genomic markers and also mutagenesis.
58:54 That's a great detail and just so I'm understanding correctly, Canonic will be growing and selling, so we expect to see some growth in the marketing team, etc., or will this be licensed out and distributed through other sales channels?
59:09 At least for now, it's in between, and I will explain. Canonic is responsible for developing the unique variety, and currently we have the authority The license to produce seedling or in a way also could be seed. And then we are planning to use third party that we are already in advanced negotiation with them that they will grow, they have the license to grow cannabis in greenhouses here in Israel. And the flowers, you know, the cannabinoids We are going to extract it from these growers and we will be responsible on the sales.
59:55 And then, you know, we can sell it through direct channels or we can use distributors, but we will be responsible also on the phase between the growing and the consumer. So we will, in high level, we will be responsible from developing the variety. Till selling the end product. But there will be pieces on the way that we are going to use third party, mainly growers, because I don't think that there is any real advantage for Evogen to invest money in a growing facility. We prefer always to use and look for the best grower of cannabis in Israel or abroad.
1:00:41 to grow it for us. If we come to the conclusion that economically or maybe there is a reason for us to move into this direction, we might decide to do so. But if this is the first year, I'm not too much excited to invest too much capital in growing facilities when other people can do it in quite competitive price to do it for us and we can be responsible and get the value There are no further questions at this time. The company would now like to answer questions received from investors prior to the call.
1:01:30 Hi, this is Kenny Green. I'm part of Edison Group, Evergene's external investor relations team. We actually have two questions submitted over email from investors. Our first question is a financial one for Dorit. Your recent deal included pre-funded warrants. Can you shed some light on what this means in terms of the company?
1:01:54 Yes, sure. The pre-funded warrants included in the second deal are actually warrants that were already paid for and we already received the money from. So actually the warrant price was 2.49, which means one cent discount versus the share price in the deal, 2.5. The reason for this structure is effectively the share price was due to wish of a particular investor that had internal limits on the amount of Evergen stock they could own, but not the warrant. So actually, and basically it was a technical solution to a technical problem. So as I said, the warrant was already paid for, there is no element of future dilution in the company, and there was practically no discount to the overall deal.
1:02:43 Okay, thank you for that. And the next question is for Ofer. Do you expect to use the funds raised recently to accelerate existing programs or enter new programs in new areas?
1:02:56 As published in our filing and as mentioned on this call, we intend to use the proceeds from the fundraising first and foremost for support of our subsidiaries' existing programs and to maintain an evident competitive edge. Okay, thank you, Ofer.
1:03:15 And that's the questions we received, so back to the operator. If there are any additional questions, please press star 1. Please stand by while we poll for your questions. Before I ask Mr. Ofer Haviv to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference. In the US, please call 1-888-326-9310 In Israel, please call 03-9255-901 Internationally, please call 972-392-55901 Mr.
1:04:01 Haviv, would you like to make your concluding statement?
1:04:03 Yes, thank you. Thank you all for joining the call today. We look forward to updating you with our progress over the next few months. Thank you and good day. Thank you. This concludes Evagen's third quarter 2020 results conference call. Thank you for your participation. You may go ahead and disconnect.
Follow Evogene Ltd. into a list and get an email when it puts out news.
Investor Relations at Edison Group
CFO
Investor at Iniksjuk Investments
Analyst
CEO of Biomica
CEO
Analyst at Cantor Fitzgerald